Lannett, KV Bury Hatchet Over Vitamin Patents

Law360, New York (March 25, 2009, 12:00 AM EDT) -- With KV Pharmaceutical Co. set to pull its Primacare One prenatal vitamin from the market, rival generic-drug maker Lannett Co. Inc. has ended its quest to invalidate KV’s patents for the supplement, opting instead to settle its declaratory suit and attain the required license.

The feuding generic-drug makers agreed to bury the hatchet, entering a consent judgment Monday in the U.S. District Court for the District of Delaware that faults Lannett for infringing three patents for supplements geared toward pregnant and nursing women.

Lannett’s competing dietary...
To view the full article, register now.